Peptide Drug Conjugates Market

Peptide Drug Conjugates Market by Product (Lutathera (lutetium Lu 177 dotatate), Pepaxti (Melphalan flufenamide), and Pluvicto (lutetium Lu 177 vipivotide tetraxetan)), Cancer Type (Prostate Cancer, Gastrointestinal Cancer, Multiple Myeloma), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising cases of cancer worldwide, growing adoption of peptide drug therapeutics owing to superior treatment outcomes and enhanced efficacy, and increase in strategic collaborations and product development activities in the domain of peptide drug conjugates across the globe.

The Peptide Drug Conjugates market was valued at USD 1,927.51 million in 2024, growing at a CAGR of 28.73% during the forecast period from 2025 to 2032 to reach USD 13,849.85 million by 2032. The rising cases of cancer worldwide are significantly driving the demand for Peptide Drug Conjugates (PDCs) as targeted therapies, offering enhanced efficacy and reduced systemic toxicity compared to traditional treatments. The growing adoption of peptide drug therapeutics, owing to their superior treatment outcomes, biocompatibility, and ability to target specific tumor cells, further accelerates market growth. Additionally, increased strategic collaborations between biotech companies, research institutions, and pharmaceutical firms are fostering innovation and expediting the development of novel PDCs. Ongoing product development activities, coupled with advancements in peptide synthesis and conjugation technologies, are expanding the therapeutic applications of PDCs, and collectively boosting the global peptide drug conjugate market during the forecast period from 2025 to 2032.

Peptide Drug Conjugates Market Dynamics:

As per the recent data provided by the International Agency for Research on Cancer (2024), in 2022, globally, the estimated number of new cases of prostate cancer was 1.47 million and the projections were estimated to increase to 2.63 million by 2045. Peptide-drug conjugates, targeting prostate cancer, such as those designed to bind prostate-specific membrane antigen (PSMA), significantly enhance treatment precision by delivering cytotoxic agents directly to cancer cells while sparing normal tissues. This targeted approach reduces toxicity and boosts therapeutic outcomes. Additionally, PDCs can stimulate an immune response by promoting tumor antigen presentation, enhancing their anti-cancer effects. Additionally, increasing pharmaceutical investments and advancements in peptide synthesis and conjugation technologies are driving the development of next-generation PDCs, making them a promising therapy for prostate cancer, and thereby boosting the market growth for peptide drug conjugates in prostate cancer. 

Additionally, as per the same source, globally, the estimated new cases of hematological malignancies such as Hodgkin lymphoma and non-Hodgkin lymphoma in 2022 were 82,500 and 553,000 respectively and the projections were indicated to reach 10,900 and 890,000 respectively by 2045. Many lymphomas express specific surface markers, such as CD19 and CD20, which can be targeted by peptides. By conjugating cytotoxic agents to these peptides, PDCs can deliver drugs directly to malignant cells, enhancing therapeutic efficacy while reducing damage to healthy tissues and hence boosting the market of PDCs.

However, the increased adoption and superior treatment outcomes with enhanced efficacy of peptide drug conjugates are driving their adoption as promising therapeutic options in oncology. By leveraging the specificity of peptides for targeted delivery, PDCs improve drug accumulation at tumor sites while minimizing systemic toxicity. For instance, a recent study developed a HER2-targeting peptide-drug conjugate (HER2-TPMC) that demonstrated superior specificity and lower cytotoxicity compared to traditional chemotherapeutic agents like mertansine. The smaller size of HER2-TPMC enables rapid tissue penetration and effective tumor uptake, resulting in better therapeutic outcomes.

For instance, in March 2024, ProteinQure, the leading startup in the computational design of peptide drugs, announced a significant breakthrough in the fight against triple-negative breast cancer (TNBC). The novel Peptide Drug Conjugate (PDC) designed by ProteinQure demonstrated exceptional efficacy in a comprehensive suite of Patient-Derived Xenograft (PDX) models.

Thus, the factors mentioned above are expected to boost the overall market of peptide drug conjugates across the globe during the forecast period from 2025 to 2032.

However, limited therapeutic potential on solid tumors low oral bioavailability, and high manufacturing costs and complexity may hinder the future market of peptide drug conjugates across the globe during the forecasted period.

Peptide Drug Conjugates Market Segment Analysis:

Peptide Drug Conjugates Market by Product (Lutathera (lutetium Lu 177 dotatate), Pepaxti (Melphalan flufenamide), and Pluvicto (lutetium Lu 177 vipivotide tetraxetan)), Cancer Type (Prostate Cancer, Gastrointestinal Cancer, Multiple Myeloma), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The Lutathera (lutetium Lu 177 dotatate) category in the peptide drug conjugates market is estimated to dominate the market with a market share of 37% in 2024. Lutathera is significantly driving the overall market for peptide drug conjugates due to its groundbreaking role in targeted cancer therapy, particularly for neuroendocrine tumors (NETs). As the first FDA-approved radiolabeled somatostatin analog, it has demonstrated exceptional efficacy in targeting somatostatin receptor-positive tumors, a capability that sets it apart in the oncology treatment landscape. One of the key advantages of Lutathera is its ability to deliver targeted radiation, reducing the side effects commonly associated with traditional chemotherapy. By binding specifically to tumor cells expressing somatostatin receptors, Lutathera minimizes damage to normal tissues, which can improve patient outcomes and quality of life.

Furthermore, Lutathera has set a precedent in the growing field of peptide receptor radionuclide therapy (PRRT), sparking further interest in developing other peptide drug conjugates for the treatment of various cancers. For instance, in April 2024, Novartis announced that the FDA approved Lutathera® (lutetium Lu 177 dotatate) for treating pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), making it the first therapy approved for pediatric GEP-NETs.

Thus, its success demonstrates the potential of radiopharmaceuticals in targeted therapy and is encouraging to drive continued investment in innovative treatments that combine peptides with radioactive agents for better precision in cancer treatment.

Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of peptide drug conjugates across the globe.

North America is expected to dominate the overall peptide drug conjugates market:

Among all regions, North America is estimated to hold the largest share of 56.70% in the global peptide drug conjugates market in 2024, growing at a CAGR of 28.47% during the forecast period from 2025 to 2032. This can be attributed to the rising cases of cancer in the U.S. Additionally, the increase in collaborations among key players for peptide drug conjugates development, and growing investments in the domain of PDCs are further propelling the overall market of PDCs across the region.

According to the American Cancer Society 2024, nearly 2 million new cancer cases are expected to be diagnosed in the United States by the end of 2024, up from 1.9 million in 2023.

As per the Centers for Disease Control and Prevention (2024), the U.S. cancer statistics recorded 1,777,566 new cases of invasive cancer occurring in 2021; comprising 272,454 breast cancers, 141,902 colorectal cancers, and 209,500 lung cancers reported in 2021. As cancer cases rise, there is a growing demand for innovative therapies that effectively target tumor cells while sparing healthy tissues. PDCs address this need by combining peptides with potent cytotoxic agents, enhancing treatment efficacy and minimizing systemic toxicity.

Additionally, key players in the region are focusing on R&D to develop innovative peptide-drug conjugates. For example, in February 2021, Theratechnologies Inc. announced that the U.S. Food and Drug Administration (FDA) had granted fast-track designation for TH1902, a docetaxel-based peptide-drug conjugate, as a monotherapy aimed at treating patients with sortilin-positive recurrent advanced solid tumors resistant to standard therapies.

Moreover, in April 2024, Novartis, with its two marketed PDC drugs approved by the FDA, collaborated with PeptiDream to expand its peptide drug conjugate development collaboration in a deal valued at more than USD 2.8 billion.

Thus, the above-mentioned factors are expected to escalate the market of peptide drug conjugates in the region.

Peptide Drug Conjugates Market Key Players:

Some of the key market players operating in the peptide drug conjugates market include Novartis AG, Oncopeptides AB, Cybrexa Therapeutics, Avacta Therapeutics, ProteinQure, Theratechnologies Inc., CBP, Soricimed Biopharma, NMS Group S.p.A., Mainline Scientific LLC., Bicycle Therapeutics, and others.

Recent Developmental Activities in the Peptide Drug Conjugates Market:

• In April 2024, PeptiDream Inc. announced the expansion of its peptide discovery collaboration with Novartis Pharma AG. Using its proprietary Peptide Discovery Platform System (PDPS®), PeptiDream identified and optimized macrocyclic peptides for conjugation with radionuclides for therapeutic and diagnostic applications. 
• In March 2023, Ono Pharmaceutical Co., Ltd. announced that it entered into a drug discovery collaboration agreement with PeptiDream Inc., to discover and develop novel macrocyclic constrained peptide drugs against multiple targets of Ono’s interest.
• In December 2022, PeptiDream Inc. announced that it entered into a Research Collaboration and License Agreement with U.S.-based Eli Lilly and Company. The agreement focused on the discovery and development of novel peptide drug conjugates (PDCs). This collaboration aimed to leverage PeptiDream's advanced peptide discovery technologies to develop innovative PDC therapies. 

Key Takeaways From the Peptide Drug Conjugates Market Report Study

• Market size analysis for current peptide drug conjugates size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the peptide drug conjugates market.
• Various opportunities are available for the other competitors in the peptide drug conjugates market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current peptide drug conjugates market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for peptide drug conjugates market growth in the coming future?

Target Audience Who Can be Benefited From This Peptide Drug Conjugates Market Report Study

• Peptide drug conjugates product providers
• Research organizations and consulting companies 
• Peptide drug conjugates -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in peptide drug conjugates 
• Various end-users who want to know more about the peptide drug conjugates market and the latest technological developments in the peptide drug conjugate market.

Frequently Asked Questions for the Peptide Drug Conjugates Market:

1. What are peptide drug conjugates?

⮚ Peptide-drug conjugates (PDCs) are an innovative class of targeted therapeutics designed for precise drug delivery, particularly in cancer treatment. They consist of three key components: a peptide, a linker, and a cytotoxic or radioactive drug. The peptide, a short amino acid sequence, selectively binds to specific receptors on target cells, enabling enhanced tissue penetration and targeted delivery.

2. What is the market for peptide drug conjugates?

⮚ The Peptide Drug Conjugates market was valued at USD 1,927.51 million in 2024, growing at a CAGR of 28.73% during the forecast period from 2025 to 2032 to reach USD 13,849.85 million by 2032. 

3. What are the drivers for the global peptide drug conjugates market?

⮚ The rising cases of cancer worldwide are significantly driving the demand for Peptide Drug Conjugates (PDCs) as targeted therapies, offering enhanced efficacy and reduced systemic toxicity compared to traditional treatments. The growing adoption of peptide drug therapeutics, owing to their superior treatment outcomes, biocompatibility, and ability to target specific tumor cells, further accelerates market growth. Additionally, increased strategic collaborations between biotech companies, research institutions, and pharmaceutical firms are fostering innovation and expediting the development of novel PDCs. Ongoing product development activities, coupled with advancements in peptide synthesis and conjugation technologies, are expanding the therapeutic applications of PDCs, and collectively boosting the global peptide drug conjugate market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global peptide drug conjugates market?

⮚ Some of the key market players operating in the peptide drug conjugates are Novartis AG, Oncopeptides AB, Cybrexa Therapeutics, Avacta Therapeutics, ProteinQure, Theratechnologies Inc., CBP, Soricimed Biopharma, NMS Group S.p.A., Mainline Scientific LLC., Bicycle Therapeutics, and others.

5. Which region has the highest share in the global peptide drug conjugates market?

⮚ North America region is anticipated to dominate the overall peptide drug conjugates market due to the rising cases of cancers in the U.S. Additionally, the increase in collaborations among key players for peptide drug conjugates development, and growing investments in the domain of PDCs are further propelling the overall market of PDCs across the region.